LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 383

Search options

  1. Book: The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC

    Hirsch, Fred R.

    (Oncogene ; 28, Suppl. 1)

    2009  

    Author's details guest ed. Fred R Hirsch
    Series title Oncogene ; 28, Suppl. 1
    Collection
    Language English
    Size S45 S.
    Publisher Nature Publ. Group
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT016054034
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 2218 -28,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast.

    Hirsch, Fred R / Kim, Chul

    Oncology and therapy

    2024  

    Abstract: The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small cell lung cancer (NSCLC), biomarker testing can inform selection of effective ... ...

    Abstract The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small cell lung cancer (NSCLC), biomarker testing can inform selection of effective targeted therapies as well as avoid therapies that are less likely to be effective in certain populations. A growing number of actionable targets, including those involving EGFR, ALK, ROS1, BRAF, MET, KRAS, NTRK, RET, HER2, and PD-L1, can be identified with biomarker testing. More than half of patients with advanced NSCLC have tumors that harbor genetic alterations that can be targeted. When these patients are treated with targeted therapy, survival and quality of life may be significantly improved. In addition, broad-based molecular testing may detect alterations identifying patients who are potentially eligible for current or future clinical trials. Comprehensive biomarker testing rates in communities are often low, and turnaround times for results can be unacceptably long. There is an unmet need for widespread, efficient, and routine testing of all biomarkers recommended by clinical guidelines. New testing techniques and technologies can make this an attainable goal. Panel-based sequencing platforms are becoming more accessible, and molecular biomarker analysis of circulating tumor DNA is becoming more common. In this podcast, we discuss the importance of biomarker testing in advanced NSCLC and explore topics such as testing methodologies, effect of biomarker testing on patient outcomes, emerging technologies, and strategies for improving testing rates in the United States. Supplementary file1 (MP4 121301 KB).
    Language English
    Publishing date 2024-03-27
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2848647-X
    ISSN 2366-1089 ; 2366-1070
    ISSN (online) 2366-1089
    ISSN 2366-1070
    DOI 10.1007/s40487-024-00271-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Textbook of prevention and detection of early lung cancer

    Hirsch, Fred R.

    2006  

    Title variant IASLC textbook of prevention and detection of early lung cancer
    Institution International Association for the Study of Lung Cancer
    Author's details International Association for the Study of Lung Cancer. Ed. by Fred R. Hirsch
    Keywords Lungs/Cancer/Prevention ; Lungs/Cancer/Diagnosis
    Subject code 616.99424052
    Language English
    Size XII, 396 S. : Ill., graph. Darst., Kt.
    Publisher Taylor & Francis
    Publishing place London u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT013767933
    ISBN 978-1-84184-301-8 ; 1-84184-301-6
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2005 A 4923 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book ; Conference proceedings: Invited papers of the First IASLC ASCO International Conference on Molecular Targeted Therapies in Lung Cancer

    Hirsch, Fred R.

    Marbella, Spain, 15th - 19th January 2003

    (Lung cancer ; 41, Suppl. 1)

    2003  

    Institution International Association for the Study of Lung Cancer
    American Society of Clinical Oncology
    Event/congress International Conference on Molecular Targeted Therapies in Lung Cancer (1, 2003, Marbella)
    Author's details guest ed.: Fred R. Hirsch
    Series title Lung cancer ; 41, Suppl. 1
    Collection
    Language English
    Size VI, S186 S. : Ill., graph. Darst.
    Publisher Elsevier
    Publishing place Amsterdam u.a.
    Publishing country Netherlands
    Document type Book ; Conference proceedings
    HBZ-ID HT013763439
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 2135 -41,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Conference proceedings: Meeting report / IV International Conference on Prevention and Early Detection of Lung Cancer

    Hirsch, Fred R.

    Reykjavik, Iceland, August 9 - 12, 2001

    2002  

    Institution International Conference on Prevention and Early Detection of Lung Cancer
    Author's details Fred R. Hirsch
    Language English
    Publishing country Netherlands
    Document type Article ; Conference proceedings
    Note In: Lung cancer. - ISSN 0169-5002. - 37 (2002),3, S. 325 - 344
    HBZ-ID HT013488450
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 2135 -37- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Programmed death ligand 1 testing: is there one best test?

    Hirsch, Fred R

    Clinical advances in hematology & oncology : H&O

    2017  Volume 15, Issue 6, Page(s) 438–440

    MeSH term(s) B7-H1 Antigen/analysis ; Biomarkers, Tumor/analysis ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Humans ; Lung Neoplasms/drug therapy
    Chemical Substances B7-H1 Antigen ; Biomarkers, Tumor ; CD274 protein, human
    Language English
    Publishing date 2017-07-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Longitudinal Analyses of COVID-19 Vaccination in Patients With Lung Cancer: Antibody Responses and Variant-Specific Neutralization.

    Mack, Philip C / Hirsch, Fred R / Bunn, Paul A / Minna, John D

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2022  Volume 40, Issue 33, Page(s) 3787–3789

    MeSH term(s) Humans ; Antibodies, Viral ; Antibody Formation ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines ; Lung Neoplasms ; Vaccination
    Chemical Substances Antibodies, Viral ; COVID-19 Vaccines
    Language English
    Publishing date 2022-06-27
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.01136
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?

    Hirsch, Fred R

    Translational lung cancer research

    2015  Volume 3, Issue 6, Page(s) 363–364

    Language English
    Publishing date 2015-03-10
    Publishing country China
    Document type Journal Article
    ZDB-ID 2754335-3
    ISSN 2226-4477 ; 2218-6751
    ISSN (online) 2226-4477
    ISSN 2218-6751
    DOI 10.3978/j.issn.2218-6751.2014.11.07
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment.

    Vergote, Ignace / Macarulla, Teresa / Hirsch, Fred R / Hagemann, Carsten / Miller, David Scott

    Cancers

    2023  Volume 15, Issue 3

    Abstract: Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated with ... ...

    Abstract Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated with systemic toxicity. Multimodal treatment combinations can help improve patient outcomes; however, implementation is limited by additive toxicities and potential drug-drug interactions. As such, there is a high unmet need to develop additional therapies to enhance the efficacy of SOC treatments without increasing toxicity. Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. The therapy is locoregional and is delivered noninvasively to the tumor site via a portable medical device that consists of field generator and arrays that are placed on the patient's skin. As a noninvasive treatment modality, TTFields therapy-related adverse events mainly consist of localized skin reactions, which are manageable with effective acute and prophylactic treatments. TTFields selectively target cancer cells through a multi-mechanistic approach without affecting healthy cells and tissues. Therefore, the application of TTFields therapy concomitant with other cancer treatments may lead to enhanced efficacy, with low risk of further systemic toxicity. In this review, we explore TTFields therapy concomitant with taxanes in both preclinical and clinical settings. The summarized data suggest that TTFields therapy concomitant with taxanes may be beneficial in the treatment of certain cancers.
    Language English
    Publishing date 2023-01-19
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15030636
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer.

    Ciardiello, Fortunato / Hirsch, Fred R / Pirker, Robert / Felip, Enriqueta / Valencia, Christian / Smit, Egbert F

    Cancer treatment reviews

    2023  Volume 122, Page(s) 102664

    Abstract: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current recommended option for the first-line treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Resistance to first-generation TKIs led to the ... ...

    Abstract Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current recommended option for the first-line treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Resistance to first-generation TKIs led to the development of second- and third-generation TKIs with improved clinical outcomes. However, sequential administration of TKIs has led to the emergence of new EGFR resistance mutations and persistent tumor cell survival. This evidence highlights the potential role of EGFR in transducing growth signals in NSCLC tumor cells. Therefore, dual inhibition of EGFR using combinations of anti-EGFR monoclonal antibodies (mAbs) and EGFR-TKIs may offer a unique treatment strategy to suppress tumor cell growth. Several clinical studies have demonstrated the benefits of dual blockade of EGFR using anti-EGFR mAbs coupled with EGFR-TKIs in overcoming treatment resistance in patients with EGFR-mutated NSCLC. However, a single treatment option may not result in the same clinical benefits in all patients with acquired resistance. Biomarkers, including EGFR overexpression, EGFR gene copy number, EGFR and KRAS mutations, and circulating tumor DNA, have been associated with improved clinical efficacy with anti-EGFR mAbs in patients with NSCLC and acquired resistance. Further investigation of biomarkers may allow patient selection for those who could benefit from anti-EGFR mAbs in combination with EGFR-TKIs. This review summarizes findings of recent studies of anti-EGFR mAbs in combination with EGFR-TKIs for the treatment of patients with EGFR-mutated NSCLC, as well as clinical evidence for potential biomarkers towards personalized targeted medicine.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; ErbB Receptors ; Protein Kinase Inhibitors/adverse effects ; Antineoplastic Agents/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Mutation ; Biomarkers ; Drug Resistance, Neoplasm
    Chemical Substances ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; Antineoplastic Agents ; Antibodies, Monoclonal ; Biomarkers ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-11-25
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 125102-8
    ISSN 1532-1967 ; 0305-7372
    ISSN (online) 1532-1967
    ISSN 0305-7372
    DOI 10.1016/j.ctrv.2023.102664
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1022: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 611: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top